NYSE$CVS
CVS Health Corp · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported an increase in total revenues but a decrease in operating income and adjusted EPS due to challenges in the Health Care Benefits segment.
CVS Health reported a 2.6% increase in total revenues for the second quarter of 2024, reaching $91.2 billion. However, GAAP diluted EPS decreased to $1.41, and Adjusted EPS decreased to $1.83, primarily due to declines in the Health Care Benefits segment. The company has revised its full-year 2024 guidance to reflect continued pressure in the Health Care Benefits segment, partially offset by strong performance in the Health Services and Pharmacy & Consumer Wellness segments.
- Total revenues increased by 2.6% to $91.2 billion compared to the prior year.
- GAAP diluted EPS was $1.41, a decrease from $1.48 in the prior year.
- Adjusted EPS was $1.83, a decrease from $2.21 in the prior year.
- Revised full-year 2024 guidance reflects challenges in the Health Care Benefits segment.
Headline financials
Revenue & EPS history
CVS Health · Revenue · Quarterly
$91.2B
Revenue by segment
CVS Health · $102B total across 3 segments · Q3 2023
- Health Services$46.9B+8.5%45.9%
- Pharmacy & Consumer Wellness$28.9B+8.1%28.3%
- Health Care Benefits$26.3B+16.8%25.8%
Forward guidance
The Company revised its full-year 2024 GAAP diluted EPS guidance to a range of $4.95 to $5.20 from at least $5.64 and revised its full-year 2024 Adjusted EPS guidance to a range of $6.40 to $6.65 from at least $7.00. The Company also revised its full-year 2024 cash flow from operations guidance to approximately $9.0 billion from at least $10.5 billion. The Company’s guidance revision reflects continued pressure in the Health Care Benefits segment, partially offset by strong performance in the Health Services and Pharmacy & Consumer Wellness segments.
Tailwinds
- Strong performance in Health Services segment
- Strong performance in Pharmacy & Consumer Wellness segment
- Focus on innovation to improve patient outcomes
- Acceleration of transparent pharmacy reimbursement models
- Increasing the use of biosimilars
Headwinds
- Continued pressure in the Health Care Benefits segment
- Revised GAAP diluted EPS guidance to a range of $4.95 to $5.20 from at least $5.64
- Revised Adjusted EPS guidance to a range of $6.40 to $6.65 from at least $7.00
- Revised cash flow from operations guidance to approximately $9.0 billion from at least $10.5 billion
- Decline in Health Care Benefits segment’s operating results due to utilization pressure and unfavorable impact of Medicare Advantage star ratings
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+0.1%
Avg return
Earnings day
+1.4%
Avg return
5 days after
+1.3%
Avg return
30 days after
56%
41 / 73 earnings
Positive
+14.9%
Q4 2024
Best reaction
-18.5%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | +14.3% | +19.1% | |
| Q4 2025 | -0.1% | +3.6% | +0.4% | |
| Q3 2025 | -1.9% | -4.6% | -2.2% | |
| Q2 2025 | -0.3% | +1.8% | +17.4% | |
| Q1 2025 | +4.1% | -0.7% | -4.0% | |
| Q4 2024 | +14.9% | +19.7% | +19.4% | |
| Q3 2024 | +3.1% | +0.8% | -0.1% | |
| Q2 2024 | -0.8% | -4.3% | -1.0% | |
| Q1 2024 | -18.5% | -17.3% | -12.0% | |
| Q4 2023 | +1.8% | +4.8% | +1.8% | |
| Q3 2023 | +0.9% | +3.0% | -0.8% | |
| Q2 2023 | +0.5% | -0.1% | -11.2% | |
| Q1 2023 | -5.5% | -4.2% | -3.8% | |
| Q4 2022 | +4.8% | +4.5% | -10.3% | |
| Q3 2022 | +3.4% | +6.9% | +8.4% | |
| Q2 2022 | +6.8% | +7.0% | +4.3% | |
| Q1 2022 | +1.8% | +3.0% | -1.1% | |
| Q4 2021 | -5.0% | -7.1% | -6.6% | |
| Q3 2021 | +3.7% | +2.9% | -0.3% | |
| Q2 2021 | -4.7% | -2.8% | +4.1% | |
| Q1 2021 | +6.9% | +9.6% | +12.1% | |
| Q4 2020 | -2.0% | -5.1% | +0.4% | |
| Q3 2020 | +10.0% | +13.2% | +21.3% | |
| Q2 2020 | -1.3% | +1.1% | -7.3% | |
| Q1 2020 | +0.4% | +4.3% | +11.7% | |
| Q4 2019 | -2.5% | -3.4% | -19.2% | |
| Q3 2019 | +6.6% | +6.6% | +11.9% | |
| Q2 2019 | +9.2% | +8.6% | +15.0% | |
| Q1 2019 | +4.3% | +4.1% | -3.7% | |
| Q4 2018 | -10.8% | -12.4% | -19.8% | |
| Q3 2018 | +6.9% | +8.3% | +3.9% | |
| Q2 2018 | +4.8% | +6.2% | +18.1% | |
| Q1 2018 | -8.4% | -9.2% | -5.8% | |
| Q4 2017 | -6.7% | -5.7% | -6.8% | |
| Q3 2017 | -0.4% | +2.5% | +3.1% | |
| Q2 2017 | +0.4% | +0.4% | +1.6% | |
| Q1 2017 | -2.8% | -1.1% | -4.5% | |
| Q4 2016 | +1.9% | +2.1% | +4.4% | |
| Q3 2016 | -8.2% | -10.0% | -6.3% | |
| Q2 2016 | +4.2% | +4.2% | -0.1% | |
| Q1 2016 | +2.4% | — | — | |
| Q4 2015 | +3.9% | — | — | |
| Q3 2015 | -3.3% | — | — | |
| Q2 2015 | -1.4% | — | — | |
| Q1 2015 | +0.9% | — | — | |
| Q4 2014 | +3.0% | — | — | |
| Q3 2014 | +1.6% | — | — | |
| Q2 2014 | -0.4% | — | — | |
| Q1 2014 | +2.6% | — | — | |
| Q4 2013 | +2.4% | — | — | |
| Q3 2013 | +3.0% | — | — | |
| Q2 2013 | -4.1% | — | — | |
| Q1 2013 | +1.3% | — | — | |
| Q4 2012 | -1.0% | — | — | |
| Q3 2012 | +0.1% | — | — | |
| Q2 2012 | +1.5% | — | — | |
| Q1 2012 | +2.9% | — | — | |
| Q4 2011 | -1.2% | — | — | |
| Q3 2011 | +6.3% | — | — | |
| Q2 2011 | -5.7% | — | — | |
| Q1 2011 | +3.9% | — | — | |
| Q4 2010 | -0.2% | — | — | |
| Q4 2007 | -0.2% | — | — | |
| Q3 2010 | +3.2% | — | — | |
| Q2 2010 | -2.7% | — | — | |
| Q1 2009 | -2.8% | — | — | |
| Q1 2010 | -2.2% | — | — | |
| Q4 2009 | +1.2% | — | — | |
| Q3 2008 | -17.6% | — | — | |
| Q3 2009 | -17.6% | — | — | |
| Q4 2008 | +1.1% | — | — | |
| Q2 2008 | +1.1% | — | — | |
| Q2 2009 | +1.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro